11-Jun-2024 | Facts and Factors
Findings from Facts and Factors report “Atopic Eczema Treatment Market Size, Share, Growth Analysis Report By Drug Class (Biologics, PDE-4 Inhibitors, Calcineurin Inhibitors, and Corticosteroids), By Route of Administration (Injectable, Topical, and Oral), By Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and By Region - Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2024 – 2032” states that the global Atopic Eczema Treatment market in 2023 was approximately USD 14.26 Billion. The market is anticipated to grow at a CAGR of 8.2% and is anticipated to reach around USD 29.15 Billion by 2032.
Atopic dermatitis is a chronic inflammatory skin condition characterized by red, itchy, swollen, and broken skin. White fluid can leak from the affected region, necessitating treatment. The atopic dermis is more common in children and can become more serious as they get older. Atopic dermatitis is caused by a genetic mutation, environmental contamination, immune system dysfunction, and skin permeability issues. Dry skin, irritants, fatigue, allergies, infection, and heat/sweating are the primary causes of atopic dermatitis. It's important to remember that these just cause atopic dermatitis symptoms; they don't cause atopic dermatitis. Atopic dermatitis (AD) is a widespread chronic skin disorder that has been linked to other atopic diseases. Although there is growing evidence of a connection with non-atopic conditions, such as autoimmune disorders, data on many autoimmune diagnoses is restricted.
Browse the full“Atopic Eczema Treatment Market Size, Share, Growth Analysis Report By Drug Class (Biologics, PDE-4 Inhibitors, Calcineurin Inhibitors, and Corticosteroids), By Route of Administration (Injectable, Topical, and Oral), By Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and By Region - Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2024 – 2032” report at https://www.fnfresearch.com/atopic-eczema-treatment-market-report
Dermatological disorders are exceedingly common in different forms all over the world. According to the World Health Organization, skin diseases affected over 900 million people in 2017. Atopic dermatitis is the most common of these diseases, affecting over 300 million people worldwide. Children make up about a quarter of the victims. The increased prevalence of this disease is projected to have a positive impact on the economy. In recent years, increased understanding of the disease's therapeutic options has aided the market's survival. Government initiatives to ensure quality and more affordable care, as well as the availability of favorable reimbursement plans, are expected to boost the sector. During the study era, developing country health growth and evolution would present new opportunities.
The infected area produces white fluid, which necessitates treatment. Atopic dermis normally starts in childhood and gets worse as you get older. Atopic dermatitis is caused by a combination of genetics, environmental toxicity, immune system dysfunction, and skin permeability issues.
Based on type market is bifurcated into categories such as topical, oral, and injectable. A Topicalcategory is estimated to hold the largest market share of the atopic eczema treatment market. The cream-based solution for treatment is making the product easy for an application, which is expected to surge a market demand in forecast years. In addition to this, based on application, the market is bifurcated into categories such as hospital pharmacies, retail pharmacies, online pharmacies, and others. Retail pharmacies are estimated to hold the largest market share of the atopic eczema market. However, online pharmacies are estimated to grow at a significant CAGR owing to the penetration of mobile phones and the emergence of numerous medicine delivery startups.
Because of new product releases, early treatment acceptance, and lifestyle improvements, North America was the largest market for the treatment of atopic dermatitis in 2019. North America emerged as the leading market for atopic dermatitis, owing to higher treatment knowledge among the target population, early acceptance of novel drugs, and better reimbursement policies, according to the regional study. Europe has the second-largest share of the market. The key driver of the demand in this area is large-scale R&D spending. The Asia-Pacific region is projected to rise the fastest between 2020 and 2026, owing to increasing demand. Due to increasing health expenditure and the availability of adequate care, the Asia-Pacific region is expected to rise the fastest between 2020 and 2026.
Top Market Players
Some major players covered in the global atopic eczema treatment market are; AbbVie Inc., AnaptysBio, Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Dermira, Inc. (acquired by Eli Lilly and Company), Encore Dermatology, Inc., Galderma S.A., Incyte Corporation, LEO Pharma A/S, Medimetriks Pharmaceuticals, Inc., Medimmune LLC. (AstraZeneca), Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, and others.
According to the 2017 Global Burden of Disease research database, atopic eczema is the leading cause of skin-related impairment, affecting up to 24 percent of the global population, according to JAAD International. Up to 23% of nurses suffer from occupational dermatitis, with daily hand washing and the use of protective gloves being major risk factors. The COVID-19 pandemic has risen in cases of skin irritation and disease in health-care workers as a result of excessive use of personal protective equipment (PPE) and chronic stress, which exacerbates atopic eczema. Hand washing is a popular recommendation for preventing the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is expected to affect more people than just health-care staff as dermatitis cases rise. As a result, the global COVID-19 pandemic is predicted to benefit the atopic eczema treatment industry.
Report Scope
Report Attribute |
Details |
Market Size in 2023 |
USD 14.26 Billion |
Projected Market Size in 2032 |
USD 29.15 Billion |
CAGR Growth Rate |
8.2% CAGR |
Base Year |
2023 |
Forecast Years |
2024-2032 |
Key Market Players |
AbbVie Inc., AnaptysBio Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Dermira Inc. (acquired by Eli Lilly and Company), Encore Dermatology Inc., Galderma S.A., Incyte Corporation, LEO Pharma A/S, Medimetriks Pharmaceuticals Inc., Medimmune LLC. (AstraZeneca), Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, and Others. |
Key Segment |
By Drug Class, By Route of Administration, By Application, and By Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East &, Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
This report segments the Atopic Eczema Treatment market as follows:
By Drug Class
- Biologics
- PDE-4 Inhibitors
- Calcineurin Inhibitors
- Corticosteroids
By Route of Administration
By Application
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Global Atopic Eczema Treatment Market: Regional Segmentation Analysis
- North America
- Europe
- Germany
- The UK
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1 (347) 690-0211
Email: [email protected]
Web: https://www.fnfresearch.com
